-
1
-
-
77951648118
-
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study
-
Advani, A., Coiffier, B., Czuczman, M.S., Dreyling, M., Foran, J., Gine, E., Gisselbrecht, C., Ketterer, N., Nasta, S., Rohatiner, A., Schmidt-Wolf, I.G., Schuler, M., Sierra, J., Smith, M.R., Verhoef, G., Winter, J.N., Boni, J., Vandendries, E., Shapiro, M. & Fayad, L. (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. Journal of Clinical Oncology, 28, 2085-2093.
-
(2010)
Journal of Clinical Oncology
, vol.28
, pp. 2085-2093
-
-
Advani, A.1
Coiffier, B.2
Czuczman, M.S.3
Dreyling, M.4
Foran, J.5
Gine, E.6
Gisselbrecht, C.7
Ketterer, N.8
Nasta, S.9
Rohatiner, A.10
Schmidt-Wolf, I.G.11
Schuler, M.12
Sierra, J.13
Smith, M.R.14
Verhoef, G.15
Winter, J.N.16
Boni, J.17
Vandendries, E.18
Shapiro, M.19
Fayad, L.20
more..
-
2
-
-
34347378243
-
How I treat patients with diffuse large B-cell lymphoma
-
Armitage, J.O. (2007) How I treat patients with diffuse large B-cell lymphoma. Blood, 110, 29-36.
-
(2007)
Blood
, vol.110
, pp. 29-36
-
-
Armitage, J.O.1
-
3
-
-
7844225540
-
Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
-
Berinstein, N.L., Grillo-López, A.J., White, C.A., Bence-Bruckler, I., Maloney, D., Czuczman, M., Green, D., Rosenberg, J., McLaughlin, P. & Shen, D. (1998) Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Annals of Oncology, 9, 995-1001.
-
(1998)
Annals of Oncology
, vol.9
, pp. 995-1001
-
-
Berinstein, N.L.1
Grillo-López, A.J.2
White, C.A.3
Bence-Bruckler, I.4
Maloney, D.5
Czuczman, M.6
Green, D.7
Rosenberg, J.8
McLaughlin, P.9
Shen, D.10
-
4
-
-
80054095609
-
SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies
-
Blanc, V., Bousseau, A., Caron, A., Carrez, C., Lutz, R.J. & Lambert, J.M. (2011) SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. Clinical Cancer Research, 17, 6448-6458.
-
(2011)
Clinical Cancer Research
, vol.17
, pp. 6448-6458
-
-
Blanc, V.1
Bousseau, A.2
Caron, A.3
Carrez, C.4
Lutz, R.J.5
Lambert, J.M.6
-
5
-
-
69949166664
-
Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma
-
Blasco, H., Chatelut, E., de Bretagne, I.B., Congy-Jolivet, N. & Le Guellec, C. (2009) Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma. Fundamental & Clinical Pharmacology, 23, 601-608.
-
(2009)
Fundamental & Clinical Pharmacology
, vol.23
, pp. 601-608
-
-
Blasco, H.1
Chatelut, E.2
de Bretagne, I.B.3
Congy-Jolivet, N.4
Le Guellec, C.5
-
6
-
-
79952092706
-
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy
-
Burris, H.A. III, Rugo, H.S., Vukelja, S.J., Vogel, C.L., Borson, R.A., Limentani, S., Tan-Chiu, E., Krop, I.E., Michaelson, R.A., Girish, S., Amler, L., Zheng, M., Chu, Y.W., Klencke, B. & O'Shaughnessy, J.A. (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. Journal of Clinical Oncology, 29, 398-405.
-
(2011)
Journal of Clinical Oncology
, vol.29
, pp. 398-405
-
-
Burris, H.A.1
Rugo, H.S.2
Vukelja, S.J.3
Vogel, C.L.4
Borson, R.A.5
Limentani, S.6
Tan-Chiu, E.7
Krop, I.E.8
Michaelson, R.A.9
Girish, S.10
Amler, L.11
Zheng, M.12
Chu, Y.W.13
Klencke, B.14
O'Shaughnessy, J.A.15
-
7
-
-
33947496614
-
Revised response criteria for malignant lymphoma
-
International Harmonization Project on Lymphoma.
-
Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V.; International Harmonization Project on Lymphoma. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
-
(2007)
Journal of Clinical Oncology
, vol.25
, pp. 579-586
-
-
Cheson, B.D.1
Pfistner, B.2
Juweid, M.E.3
Gascoyne, R.D.4
Specht, L.5
Horning, S.J.6
Coiffier, B.7
Fisher, R.I.8
Hagenbeek, A.9
Zucca, E.10
Rosen, S.T.11
Stroobants, S.12
Lister, T.A.13
Hoppe, R.T.14
Dreyling, M.15
Tobinai, K.16
Vose, J.M.17
Connors, J.M.18
Federico, M.19
Diehl, V.20
more..
-
8
-
-
84864517049
-
Diffuse large B-cell lymphoma: current strategies and future directions
-
Cultrera, J.L. & Dalia, S.M. (2012) Diffuse large B-cell lymphoma: current strategies and future directions. Cancer Control, 19, 204-213.
-
(2012)
Cancer Control
, vol.19
, pp. 204-213
-
-
Cultrera, J.L.1
Dalia, S.M.2
-
9
-
-
84939240229
-
Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL)
-
Forero-Torres, A., Moskowitz, C., Advani, R.H., Shah, B.D., Kostic, A., Albertson, T.M., Sandalic, L., Zhao, B. & Fanale, M.A. (2014) Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL). Journal of Clinical Oncology (ASCO Annual Meeting Abstracts), 32, 8505.
-
(2014)
Journal of Clinical Oncology (ASCO Annual Meeting Abstracts)
, vol.32
, pp. 8505
-
-
Forero-Torres, A.1
Moskowitz, C.2
Advani, R.H.3
Shah, B.D.4
Kostic, A.5
Albertson, T.M.6
Sandalic, L.7
Zhao, B.8
Fanale, M.A.9
-
10
-
-
77957965500
-
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era
-
Gisselbrecht, C., Glass, B., Mounier, N., Singh, G.D., Linch, D.C., Trneny, M., Bosly, A., Ketterer, N., Shpilberg, O., Hagberg, H., Ma, D., Briere, J., Moskowitz, C.H. & Schmitz, N. (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. Journal of Clinical Oncology, 28, 4184-4190.
-
(2010)
Journal of Clinical Oncology
, vol.28
, pp. 4184-4190
-
-
Gisselbrecht, C.1
Glass, B.2
Mounier, N.3
Singh, G.D.4
Linch, D.C.5
Trneny, M.6
Bosly, A.7
Ketterer, N.8
Shpilberg, O.9
Hagberg, H.10
Ma, D.11
Briere, J.12
Moskowitz, C.H.13
Schmitz, N.14
-
11
-
-
84873085382
-
Phase I/II study of MEDI-551, a humanized monoclonal antibody targeting CD19, in subjects with relapsed or refractory advanced B-cell malignancies
-
abstract.
-
Goswami, T., Forero, A., Hamadani, M., Sonet, A., Verhoef, G., Fanale, M.A., Bello, C.M., Huang, W. & Cheson, B.D. (2012) Phase I/II study of MEDI-551, a humanized monoclonal antibody targeting CD19, in subjects with relapsed or refractory advanced B-cell malignancies. Journal of Clinical Oncology (ASCO Annual Meeting Abstracts), 30, abstract 8065.
-
(2012)
Journal of Clinical Oncology (ASCO Annual Meeting Abstracts)
, vol.30
, pp. 8065
-
-
Goswami, T.1
Forero, A.2
Hamadani, M.3
Sonet, A.4
Verhoef, G.5
Fanale, M.A.6
Bello, C.M.7
Huang, W.8
Cheson, B.D.9
-
12
-
-
84941997487
-
Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment
-
Hitz, F., Connors, J.M., Gascoyne, R.D., Hoskins, P., Moccia, A., Savage, K.J., Sehn, L.H., Shenkier, T., Villa, D. & Klasa, R. (2015) Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment. Annals of Hematology, 94, 1839-1843.
-
(2015)
Annals of Hematology
, vol.94
, pp. 1839-1843
-
-
Hitz, F.1
Connors, J.M.2
Gascoyne, R.D.3
Hoskins, P.4
Moccia, A.5
Savage, K.J.6
Sehn, L.H.7
Shenkier, T.8
Villa, D.9
Klasa, R.10
-
13
-
-
0036096946
-
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel
-
Ibrahim, N.K., Desai, N., Legha, S., Soon-Shiong, P., Theriault, R.L., Rivera, E., Esmaeli, B., Ring, S.E., Bedikian, A., Hortobagyi, G.N. & Ellerhorst, J.A. (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clinical Cancer Research, 8, 1038-1044.
-
(2002)
Clinical Cancer Research
, vol.8
, pp. 1038-1044
-
-
Ibrahim, N.K.1
Desai, N.2
Legha, S.3
Soon-Shiong, P.4
Theriault, R.L.5
Rivera, E.6
Esmaeli, B.7
Ring, S.E.8
Bedikian, A.9
Hortobagyi, G.N.10
Ellerhorst, J.A.11
-
14
-
-
84923918743
-
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
-
Jacobsen, E.D., Sharman, J.P., Oki, Y., Advani, R.H., Winter, J.N., Bello, C.M., Spitzer, G., Palanca-Wessels, M.C., Kennedy, D.A., Levine, P., Yang, J. & Bartlett, N.L. (2015) Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood, 125, 1394-1402.
-
(2015)
Blood
, vol.125
, pp. 1394-1402
-
-
Jacobsen, E.D.1
Sharman, J.P.2
Oki, Y.3
Advani, R.H.4
Winter, J.N.5
Bello, C.M.6
Spitzer, G.7
Palanca-Wessels, M.C.8
Kennedy, D.A.9
Levine, P.10
Yang, J.11
Bartlett, N.L.12
-
15
-
-
84883893621
-
The impact of MYC rearrangements and "double hit" abnormalities in diffuse large B-cell lymphoma
-
Lin, P. & Medeiros, L.J. (2013) The impact of MYC rearrangements and "double hit" abnormalities in diffuse large B-cell lymphoma. Current Hematologic Malignancy Reports, 8, 243-252.
-
(2013)
Current Hematologic Malignancy Reports
, vol.8
, pp. 243-252
-
-
Lin, P.1
Medeiros, L.J.2
-
16
-
-
84902966209
-
A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma
-
Mian, M., Augustin, F., Kocher, F., Gunsilius, E., Willenbacher, W., Zabernigg, A., Zangerl, G., Oexle, H., Schreieck, S., Schnallinger, M. & Fiegl, M. (2014) A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma. Anticancer Research, 34, 2559-2564.
-
(2014)
Anticancer Research
, vol.34
, pp. 2559-2564
-
-
Mian, M.1
Augustin, F.2
Kocher, F.3
Gunsilius, E.4
Willenbacher, W.5
Zabernigg, A.6
Zangerl, G.7
Oexle, H.8
Schreieck, S.9
Schnallinger, M.10
Fiegl, M.11
-
18
-
-
84924349350
-
Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL)
-
5s, abstract.
-
Morschhauser, F., Flinn, I., Advani, R.H., Sehn, L.H., Kolibaba, K.S., Press, O.W., Salles, G.A., Diefenbach, C.S.M., Tilly, H., Assouline, S.E., Chen, A.T.Y., Dreyling, M.H., Hagenbeek, A., Zinzani, P.L., Cheson, B.D., Yalamanchili, S., Lu, D., Chai, A., Chu, Y.W. & Sharman, J.P. (2014) Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). Journal of Clinical Oncology (ASCO Annual Meeting Abstracts), 32:5s, abstract 8519.
-
(2014)
Journal of Clinical Oncology (ASCO Annual Meeting Abstracts)
, vol.32
, pp. 8519
-
-
Morschhauser, F.1
Flinn, I.2
Advani, R.H.3
Sehn, L.H.4
Kolibaba, K.S.5
Press, O.W.6
Salles, G.A.7
Diefenbach, C.S.M.8
Tilly, H.9
Assouline, S.E.10
Chen, A.T.Y.11
Dreyling, M.H.12
Hagenbeek, A.13
Zinzani, P.L.14
Cheson, B.D.15
Yalamanchili, S.16
Lu, D.17
Chai, A.18
Chu, Y.W.19
Sharman, J.P.20
more..
-
19
-
-
84886992205
-
Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial
-
Mounier, N., El, G.T., Tilly, H., Canioni, D., Sebban, C., Casasnovas, R.O., Delarue, R., Sonet, A., Beaussart, P., Petrella, T., Castaigne, S., Bologna, S., Salles, G., Rahmouni, A., Gaulard, P. & Haioun, C. (2013) Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica, 98, 1726-1731.
-
(2013)
Haematologica
, vol.98
, pp. 1726-1731
-
-
Mounier, N.1
El, G.T.2
Tilly, H.3
Canioni, D.4
Sebban, C.5
Casasnovas, R.O.6
Delarue, R.7
Sonet, A.8
Beaussart, P.9
Petrella, T.10
Castaigne, S.11
Bologna, S.12
Salles, G.13
Rahmouni, A.14
Gaulard, P.15
Haioun, C.16
-
20
-
-
84859609431
-
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL
-
Muller, C., Murawski, N., Wiesen, M.H., Held, G., Poeschel, V., Zeynalova, S., Wenger, M., Nickenig, C., Peter, N., Lengfelder, E., Metzner, B., Rixecker, T., Zwick, C., Pfreundschuh, M. & Reiser, M. (2012) The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood, 119, 3276-3284.
-
(2012)
Blood
, vol.119
, pp. 3276-3284
-
-
Muller, C.1
Murawski, N.2
Wiesen, M.H.3
Held, G.4
Poeschel, V.5
Zeynalova, S.6
Wenger, M.7
Nickenig, C.8
Peter, N.9
Lengfelder, E.10
Metzner, B.11
Rixecker, T.12
Zwick, C.13
Pfreundschuh, M.14
Reiser, M.15
-
21
-
-
84883377128
-
Targeting CD19 in B-cell lymphoma: emerging role of SAR3419
-
Raufi, A., Ebrahim, A.S. & Al-Katib, A. (2013) Targeting CD19 in B-cell lymphoma: emerging role of SAR3419. Cancer Management and Research, 5, 225-233.
-
(2013)
Cancer Management and Research
, vol.5
, pp. 225-233
-
-
Raufi, A.1
Ebrahim, A.S.2
Al-Katib, A.3
-
22
-
-
84892172931
-
A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
-
Ribrag, V., Dupuis, J., Tilly, H., Morschhauser, F., Laine, F., Houot, R., Haioun, C., Copie, C., Varga, A., Lambert, J., Hatteville, L., Ziti-Ljajic, S., Caron, A., Payrard, S. & Coiffier, B. (2014) A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clinical Cancer Research, 20, 213-220.
-
(2014)
Clinical Cancer Research
, vol.20
, pp. 213-220
-
-
Ribrag, V.1
Dupuis, J.2
Tilly, H.3
Morschhauser, F.4
Laine, F.5
Houot, R.6
Haioun, C.7
Copie, C.8
Varga, A.9
Lambert, J.10
Hatteville, L.11
Ziti-Ljajic, S.12
Caron, A.13
Payrard, S.14
Coiffier, B.15
-
23
-
-
84964994916
-
Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies
-
Scott, D.W., Mottok, A., Ennishi, D., Wright, G.W., Farinha, P., Ben-Neriah, S., Kridel, R., Barry, G.S., Hother, C., Abrisqueta, P., Boyle, M., Meissner, B., Telenius, A., Savage, K.J., Sehn, L.H., Slack, G.W., Steidl, C., Staudt, L.M., Connors, J.M., Rimsza, L.M. & Gascoyne, R.D. (2015) Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. Journal of Clinical Oncology, 33, 2848-2856.
-
(2015)
Journal of Clinical Oncology
, vol.33
, pp. 2848-2856
-
-
Scott, D.W.1
Mottok, A.2
Ennishi, D.3
Wright, G.W.4
Farinha, P.5
Ben-Neriah, S.6
Kridel, R.7
Barry, G.S.8
Hother, C.9
Abrisqueta, P.10
Boyle, M.11
Meissner, B.12
Telenius, A.13
Savage, K.J.14
Sehn, L.H.15
Slack, G.W.16
Steidl, C.17
Staudt, L.M.18
Connors, J.M.19
Rimsza, L.M.20
Gascoyne, R.D.21
more..
-
24
-
-
84930677530
-
STARLYTE: phase II study of coltuximab ravtansine (SAR3419) single agent: clinical activity and safety in patients with relapsed/refractory diffuse large B-cell lymphoma (NCT01472887)
-
5s, abstract.
-
Trneny, M., Verhoef, G., Dyer, M.J.S., Ben Yehuda, D., Patti, C., Canavese, M., Lopez, A., Awan, F., Montgomery, P., Janikova, A., Barbui, A.M., Sulek, K., Terol, M.J., Radford, J., Siraudin, L., Hatteville, L., Schwab, S., Oprea, C. & Gianni, A. (2014) STARLYTE: phase II study of coltuximab ravtansine (SAR3419) single agent: clinical activity and safety in patients with relapsed/refractory diffuse large B-cell lymphoma (NCT01472887). Journal of Clinical Oncology (ASCO Annual Meeting Abstracts), 32:5s, abstract 8506.
-
(2014)
Journal of Clinical Oncology (ASCO Annual Meeting Abstracts)
, vol.32
, pp. 8506
-
-
Trneny, M.1
Verhoef, G.2
Dyer, M.J.S.3
Ben Yehuda, D.4
Patti, C.5
Canavese, M.6
Lopez, A.7
Awan, F.8
Montgomery, P.9
Janikova, A.10
Barbui, A.M.11
Sulek, K.12
Terol, M.J.13
Radford, J.14
Siraudin, L.15
Hatteville, L.16
Schwab, S.17
Oprea, C.18
Gianni, A.19
-
25
-
-
84925719974
-
Treatment of relapsed/refractory diffuse large B-cell lymphoma with the bispecific T-cell engager (TiTE) antibody construct blinatumomab: primary analysis results from an open-label, Phase 2 study
-
Viardot, A., Goebeler, M., Hess, G., Neumann, S., Pfreundschuh, M., Adrian, N., Zettl, F., Libicher, M., Degenhard, E., Stieglmaier, J., Zhang, A., Nagorsen, D. & Bargou, R.C. (2014) Treatment of relapsed/refractory diffuse large B-cell lymphoma with the bispecific T-cell engager (TiTE) antibody construct blinatumomab: primary analysis results from an open-label, Phase 2 study. Blood (ASH Annual Meeting Abstracts), 124, 4460.
-
(2014)
Blood (ASH Annual Meeting Abstracts)
, vol.124
, pp. 4460
-
-
Viardot, A.1
Goebeler, M.2
Hess, G.3
Neumann, S.4
Pfreundschuh, M.5
Adrian, N.6
Zettl, F.7
Libicher, M.8
Degenhard, E.9
Stieglmaier, J.10
Zhang, A.11
Nagorsen, D.12
Bargou, R.C.13
-
26
-
-
84864544136
-
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma
-
Younes, A., Kim, S., Romaguera, J., Copeland, A., de Castro Farial, S., Kwak, L.W., Fayad, L., Hagemeister, F., Fanale, M., Neelapu, S., Lambert, J.M., Morariu-Zamfir, R., Payrard, S. & Gordon, L.I. (2012) Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. Journal of Clinical Oncology, 30, 2776-2782.
-
(2012)
Journal of Clinical Oncology
, vol.30
, pp. 2776-2782
-
-
Younes, A.1
Kim, S.2
Romaguera, J.3
Copeland, A.4
de Castro Farial, S.5
Kwak, L.W.6
Fayad, L.7
Hagemeister, F.8
Fanale, M.9
Neelapu, S.10
Lambert, J.M.11
Morariu-Zamfir, R.12
Payrard, S.13
Gordon, L.I.14
|